myelodysplastic syndromes (MDS) | Page 2 | Aplastic Anemia & MDS International Foundation

myelodysplastic syndromes (MDS)

Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes

Author(s): 
Hsu J, Reilly A, Hayes BJ, Clough CA, Konnick EQ, Torok-Storb B, Gulsuner S, Wu D, Becker PS, Keel SB, Abkowitz JL, Doulatov S
Primary Author: 
Hsu J
Journal Title: 
Blood
Original Publication Date: 
Apr 2019

Myeloid neoplasms, including

Bone Marrow Diseases: 

MDS with 5q deletion and rare cKIT positive mastocytosis: a diagnostic and therapeutic challenge

Author(s): 
Sanders DS, Fennell T, Chisti MM
Primary Author: 
Sanders DS
Journal Title: 
BMJ Case Reports
Original Publication Date: 
Apr 2019

A patient with a diagnosis of myelodysplastic syndrome (MDS) with isolated 5q deletion underwent repeat

Bone Marrow Diseases: 

Clonal Hematopoiesis and therapy related MDS/AML

Author(s): 
Desai P, Roboz GJ
Primary Author: 
Desai P
Journal Title: 
Best Practice & Research. Clinical Heamatology
Original Publication Date: 
Mar 2019

Clonal Hematopoiesis is defined as the presence of mutations in peripheral blood in the absence of myeloid malignancies and is thought to occur as a normal part of ageing due to the fitness advantage conferred by these mutations in an ageing hematopoietic compartment.

Bone Marrow Diseases: 

A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS)

Author(s): 
Sallman DA, Komrokji RS, Sweet KL, Mo Q, McGraw KL, Duong VH, Zhang L, Nardelli LA, Padron E, List AF, Lancet JE.
Primary Author: 
Sallman DA
Journal Title: 
Leukemia Research
Original Publication Date: 
Mar 2019

Hypomethylating agent (HMA) failure myelodysplastic syndrome (MDS) patients have poor outcomes and urgent need for novel therapies. Hedgehog pathway signaling upregulation plays a central role in myeloid neoplasm pathogenesis and leukemia stem cell survival. We evaluated the efficacy and safety of the smoothened inhibitor glasdegib in HMA-failure MDS (n = 35, median age 73 years). According to the

Bone Marrow Diseases: 

Paroxysmal nocturnal hemoglobinuria testing in patients with myelodysplastic syndrome in clinical practice-frequency and indications.

Author(s): 
Wong SA, Dalal BI, Leitch HA
Primary Author: 
Wong SA
Journal Title: 
Curr Oncol
Original Publication Date: 
Oct 2018
Background:

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Author(s): 
Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell P
Primary Author: 
Haase D
Journal Title: 
Leukemia
Original Publication Date: 
Jan 2019
Risk stratification is critical in the care of patients with
Bone Marrow Diseases: 

Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes.

Author(s): 
Zeidan AM, Klink AJ, McGuire M, Feinberg B.
Primary Author: 
Zeidan AM
Journal Title: 
Leuk Lymphoma.
Original Publication Date: 
Jan 2019
Bone Marrow Diseases: 

Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes.

Author(s): 
Hamilton BK, Rybicki L, Hirsch C, Przychodzen B, Nazha A, Gerds AT, Hanna R, Kalaycio M, Sekeres MA, Sobecks R, de Lima M, Majhail NS, Maciejewski J.
Primary Author: 
Hamilton BK
Journal Title: 
Bone Marrow Transplant
Original Publication Date: 
Jan 2019
Next generation sequencing (NGS) has become an important tool to inform disease risk for myeloid malignancies, however data remains conflicting regarding the significance of individual mutations. We performed targeted NGS on 112 patients with AML, and 80 with MDS, who underwent allogeneic hematopoietic cell transplantation. The most common mutations in AML were TET2 (14.7%), FLT3 (12.9%), DNMT3A (12.1%), and RUNX1 (7.8%). Complex
Bone Marrow Diseases: 

Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant.

Author(s): 
Fozza C.
Primary Author: 
Fozza C.
Journal Title: 
Crit Rev Oncol Hematol
Original Publication Date: 
Jan 2019
Several findings suggest that the pathogenesis and clinical history of
Bone Marrow Diseases: